TAYSHA GENE THERAPIES INC (TSHA)

US8776191061 - Common Stock

2.05  +0.13 (+6.77%)

After market: 2.05 0 (0%)

Free users can only see 4 years or quarters

Examples of complete financials are available for MSFT and AAPL.

Please register or login for additional data.

TTM
(2024-9-30)
2023
(2023-12-31)
2022
(2022-12-31)
2021
(2021-12-31)
2020
(2020-12-31)
Revenue
9.91M15.45M2.50M0.000.00
Operating Expenses
92.40M86.83M128.53M173.27M43.00M
Research and Development
63.36M56.78M91.17M131.94M31.89M
Selling, General, and Administrative Expenses
29.04M30.05M37.36M41.32M11.11M
Operating Income
-82.49M-71.37M-126.03M-173.27M-43.00M
Interest Income/Expense
6.37M-1.43M-3.55M-1.26M20.00K
Other Income/Expense
60.03M-36.30M-20.00K0.00-17.03M
Non Recurring Items
N/A-2.46M-36.42MN/AN/A
Income Before Taxes
-22.77M-111.57M-166.01M-174.52M-60.01M
Net Income
-22.77M-111.57M-166.01M-174.52M-60.01M
EBITDA
-81.18M-70.00M-124.86M-172.78M-42.99M
 
Per Share Data
EPS Diluted Total Ops
-0.06-0.96-3.78-4.64-1.74
Non GAAP EPS
0.630.13-3.13-4.63N/A
 
Statistics
Profit Margin
-229.67%-722.06%-6640.40%N/AN/A
Operating Profit Margin
-831.93%-461.94%-5041.20%N/AN/A

All data in USD

Charts